Anne-Vibeke Lænkholm

Anne-VibekeMolecular subtyping in breast carcinoma, Danish experiences.
Presentation (PDF)

The recently published ASCO1 guidelines concerning the use of biomarkers to guide decisions on adjuvant systemic therapy for early breast cancer patients includes for the first time second generation prognostic gene signatures in the panel of eligible analyses (level IB evidence).
This presentation will focus on the application of PAM50 in a subset of Danish breast cancer patients, identifying patients with a very low 10-year risk of distant recurrence. The test allows for considerations of omitting chemotherapy in these patients.

  1. Harris, L.N., et al., Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol, 2016. 34(10): p 1134-50.


Dr. Anne-Vibeke Lænkholm is a senior consultant at the Department of Pathology, Zealand University Hospital, and associate professor at the University of Copenhagen. Her main interest is diagnostic breast pathology and translational breast cancer research. She is a board member of The Danish Breast Cancer Group (DBCG), member of the NordiQC HER-2 ISH Assessor Group and member of the EWGBSP. She has 48 peer reviewed publications in scientific journals.

Selected references

  1. Analytical validation of a standardized scoring protocol for Ki67: phase 3 of an international multicenter collaboration. Samuel CY Leung, Torsten O Nielsen, Lila Zabaglo, Indu Arun, Sunil S Badve, Anita L Bane, John MS Bartlett, Signe Borgquist, Martin C Chang, Andrew Dodson, Rebecca A Enos, Susan Fineberg, Cornelia M Focke, Dongxia Gao, Allen M Gown, Dorthe Grabau, Carolina Gutierrez, Judith C Hugh, Zuzana Kos, Anne-Vibeke Lænkholm et. al. on behalf of the International Ki67 in Breast Cancer Working Group of the Breast International Group and North American Breast Cancer Group (BIG-NABCG).  npj Breast Cancer (2016) 2, 16014 doi:10.1038/npjbcancer.2016.14.

  2. Evaluation of Nine Somatic Variant Callers for Detection of Somatic Mutations in Exome and Targeted Deep Sequencing Data. Krøigård AB, Thomassen M, Lænkholm AV, Kruse TA, Larsen MJ. PLoS One. 2016 Mar 22;11(3):e0151664. doi: 10.1371/journal.pone.0151664. eCollection 2016.

  3. Thrane S, Pedersen AM, Thomsen MB, Kirkegaard T, Rasmussen BB, Duun-Henriksen AK, Lænkholm AV, Bak M, Lykkesfeldt AE, Yde CW. A kinase inhibitor screen identifies Mcl-1 and Aurora kinase A as novel treatment targets in antiestrogen-resistant breast cancer cells. Oncogene. 2015 Aug 6;34(32):4199-210. doi: 10.1038/onc.2014.351

  4. Knoop AS, Lænkholm AV, Jensen MB, Nielsen KV, Andersen J, Nielsen D, Ejlertsen B; Danish Breast Cancer Cooperative Group. Estrogen receptor, Progesterone receptor, HER2 status and Ki67 index and responsiveness to adjuvant tamoxifen in postmenopausal high-risk breast cancer patients enrolled in the DBCG 77C trial. Eur J Cancer. 2014 May;50(8):1412-21.